健亞生物科技股份有限公司
健亞生物科技股份有限公司（Genovate Biotechnology Co., Ltd.）研發製造並銷售抗感染新藥與學名藥。提供用於心血管、消化、及自體免疫疾病之藥物及 API。亦生產緩釋劑型西藥及化妝品。公司成立於 1982 年，總部位於台灣新竹。
該股 RSI(6) 為 41.3，處於中性區間，短線無明顯超買超賣訊號。股價跌破5日、20日、60日、120日均線。KD 指標中性（K=31.3）；MACD 柱狀體為負值，空方動能持續。 （自動產生 · 非投資建議）
| 日期 | 外資 | 投信 | 自營商 | 合計 |
|---|---|---|---|---|
| 07-21 | +83 | 0 | 0 | -150 |
| 07-20 | +11 | 0 | 0 | +11 |
| 07-17 | -2 | 0 | +1 | -1 |
| 07-16 | 0 | 0 | +1 | -1 |
| 07-15 | -10 | 0 | 0 | -10 |
| 07-14 | +35 | 0 | +2 | +36 |
| 07-13 | +138 | 0 | +4 | +140 |
| 07-09 | +42 | 0 | +2 | +42 |
| 07-08 | +3 | 0 | +1 | +3 |
| 07-07 | -5 | 0 | 0 | -5 |
| 07-06 | +54 | 0 | +2 | +46 |
| 07-03 | +6 | 0 | 0 | +6 |
| 07-02 | +143 | 0 | +2 | +143 |
| 07-01 | +289 | 0 | +4 | +290 |
| 06-30 | +214 | 0 | 0 | +214 |
| 06-29 | +192 | 0 | 0 | +180 |
| 06-26 | 0 | 0 | +3 | 0 |
| 06-25 | +14 | 0 | +2 | +15 |
| 06-24 | +23 | 0 | +3 | +24 |
| 06-23 | +7 | 0 | +1 | +7 |
| 06-22 | +19 | 0 | +14 | +19 |
| 06-18 | +14 | 0 | +10 | +14 |
| 06-17 | +47 | 0 | 0 | +47 |
| 06-16 | +12 | 0 | 0 | +12 |
| 06-15 | -17 | 0 | +1 | -17 |
| 06-12 | +34 | 0 | +2 | +35 |
| 06-11 | -2 | 0 | +2 | -1 |
| 06-10 | +44 | 0 | +3 | +46 |
| 06-09 | +6 | 0 | +2 | +7 |
| 06-08 | -10 | 0 | +3 | -8 |
| 06-05 | +6 | 0 | 0 | +6 |
| 06-04 | +62 | 0 | +1 | +63 |
| 06-03 | +15 | 0 | +4 | +17 |
| 06-02 | -41 | 0 | +1 | -40 |
| 06-01 | -9 | 0 | +30 | -11 |
| 05-29 | +41 | 0 | +2 | +42 |
| 月份 | 營收 | MoM% | YoY% |
|---|---|---|---|
| 2026/04 | 3960 萬 | +18.4% | -13.8% |
| 2026/03 | 3345 萬 | +22.3% | -25.9% |
| 2026/02 | 2735 萬 | -44.8% | -27.4% |
| 2026/01 | 4958 萬 | +34.1% | +2.3% |
| 2025/12 | 3696 萬 | -14.4% | -4.5% |
| 2025/11 | 4316 萬 | +9.9% | +14.0% |
| 2025/10 | 3928 萬 | +8.2% | -5.8% |
| 2025/09 | 3629 萬 | -2.7% | -15.3% |
| 2025/08 | 3730 萬 | -11.1% | -11.0% |
| 2025/07 | 4194 萬 | +3.1% | +0.8% |
| 2025/06 | 4068 萬 | +2.8% | -3.5% |
| 2025/05 | 3956 萬 | - | -11.4% |